Subscribe via RSS Feed Connect on YouTube

Congressman Keating Testifies on Opioid Epidemic

Filed in NEWS HEADLINES, politics, Uncategorized by on October 12, 2017 0 Comments • views: 428

Congressman Testifies on Opioid Epidemic
Congressman William Keating offers words before the House Energy and Commerce Committee

Washington, DC (October 11, 2017) — Wednesday, the House Energy and Commerce Committee held a member hearing on the opioid epidemic. Congressman Keating, who represents the hardest hit areas of Massachusetts, was one of the members who testified.

“Dating back to my time as District Attorney, I have witnessed the devastation of the opioid crisis for nearly two decades.  Countless families in my area have felt the effects, including my own.  I have been called to sites of unattended deaths resulting from overdose.  I have consoled parents who have lost a child to an overdose.  I have worked with grandparents who are raising their grandchildren because of addiction.  And all of this was before I got to Congress seven years ago, when the number of opioid-related deaths was 45 percent lower than it is today. Today, we even have entire facilities dedicated to babies born addicted to opioids.  As the Members of this Committee know, we cannot continue only to talk about this at arm’s length.  This goes beyond just numbers or statistics.  People are feeling real pain.  And we are losing an entire generation.

The district I represent in Congress includes four of the top five counties in Massachusetts by opioid death rate.  Further, Fall River, Massachusetts, a city I represent along with Congressman Kennedy, is projected to see at least 1,000 opioid overdoses and over 100 deaths in 2017 alone.  This is a horrible scourge for my constituents, and as evinced by the need for this hearing, a tragic epidemic nationwide.

To begin, I thank this Committee for their work guiding the House through enactment of two important laws, laws which laid meaningful groundwork for progress in battling the opioid crisis.  The strategy outlined in the Comprehensive Addiction and Recovery Act (CARA) and the $1 billion in funding included in the 21st Century Cures Act have been significant steps in the right direction.  More people have access to treatment, more health professionals understand early signs of addiction, and the number of opioid prescriptions has declined.  However, some of the health legislation we have seen this year places this progress at risk.

Prior to the Affordable Care Act (ACA), an estimated 34 percent of insurance plans did not cover treatment for opioid use and other substance use disorders, and 18 percent did not provide coverage for any mental health conditions. The ACA required insurance policies to include this coverage.  Similarly, the law’s Medicaid expansion provided access to treatment for substance use disorders to 11 million low-income Americans.In fact, at an estimated $60 billion in coverage for behavioral health services each year, Medicaid is the largest source of funding for mental healthcare in the country—including services related to substance use disorders. Efforts to repeal the Affordable Care Act and cut funding for Medicaid place this coverage at grave risk.  Accordingly, I am committed to defending the Affordable Care Act and preserving access to addiction treatment for all Americans.

Aside from these concerns, I am encouraged that we do find consensus elsewhere.  For example, we agree the solution to this crisis requires a multipronged approach.  Last Congress, I introduced three bipartisan pieces of legislation aimed at combatting the opioid crisis from three different fronts.  The first, the Stop Tampering of Prescription Pills Act, calls on the Food and Drug Administration to facilitate the creation of tamper-resistant formulations for commonly misused pain medication.  The second, the Co-Prescribing Saves Lives Act, encourages physicians to co-prescribe naloxone alongside opioid prescriptions and make naloxone more widely available in federal health settings.  The legislation also authorizes a grants program to funds state-level efforts to encourage the establishment of co-prescribing guidelines, assist in the purchase of naloxone, fund training for health professionals and patients, and support patient co-pays.  Last, the Safe Prescribing for Veterans Act outlines a common-sense plan to decrease opioid overuse among veterans by establishing a pain management continuing education requirement for opioid prescribers affiliated with the Department of Veterans Affairs.  I look forward to working with my colleagues as I reintroduce these initiatives this Congress.

We in this House are constantly learning about innovative approaches to pain management, improved methods of treating addiction, and novel ideas for opioid disorder prevention and education.  There are even technologies that function as alternatives to pain medications, such as spinal cord stimulators implanted as long-term solutions to chronic pain.  I appear before this Committee ready to work on new approaches to caring for those who need help and ensuring our families, our neighbors, and all Americans have the resources they need as they seek a path down the road to recovery.”


Leave a Reply

Your email address will not be published. Required fields are marked *